Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease.

MLA

Nyman, Jeffry S., et al. “Combined Treatment with a Transforming Growth Factor Beta Inhibitor (1D11) and Bortezomib Improves Bone Architecture in a Mouse Model of Myeloma-Induced Bone Disease.” Bone, vol. 91, Oct. 2016, pp. 81–91. EBSCOhost, https://doi.org/10.1016/j.bone.2016.07.007.

APA

Nyman, J. S., Merkel, A. R., Uppuganti, S., Nayak, B., Rowland, B., Makowski, A. J., Oyajobi, B. O., & Sterling, J. A. (2016). Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease. Bone, 91, 81–91. https://doi.org/10.1016/j.bone.2016.07.007

Chicago

Nyman, Jeffry S, Alyssa R Merkel, Sasidhar Uppuganti, Bijaya Nayak, Barbara Rowland, Alexander J Makowski, Babatunde O Oyajobi, and Julie A Sterling. 2016. “Combined Treatment with a Transforming Growth Factor Beta Inhibitor (1D11) and Bortezomib Improves Bone Architecture in a Mouse Model of Myeloma-Induced Bone Disease.” Bone 91 (October): 81–91. doi:10.1016/j.bone.2016.07.007.